Findings
DISEASE, MEDULLOBLASTOMA
In this single-arm, phase 2 nonrandomized controlled trial of 40 patients with previously irradiated recurrent or refractory medulloblastoma, a response rate of 45% was achieved. Six patients achieved a complete response, 9 patients achieved a partial response, and 5 patients had stable disease.